Share Prices & Company Research

Market News

07 Dec 2021 | 07:46

GSK-Vir drug works against all Omicron variants - study

(Sharecast News) - GlaxoSmithKline and Vir Biotechnology on Tuesday said their antibody Covid-19 treatment was effective against all mutations of the Omicron variant, according to early-stage studies. The preclinical data showed the sotrovimab treatment was effective against the 37 known mutations of the Omicron variant, GSK said in a statement.

"These pre-clinical data demonstrate the potential for our monoclonal antibody to be effective against the latest variant, Omicron, plus all other variants of concern defined to date by the WHO, and we look forward to discussing these results with regulatory authorities around the world," it added.

VIR CEO said he was confident that sotrovimab "will continue to provide significant benefit for the early treatment of patients hoping to avoid the most severe consequences of Covid-19".
Get in touch today
Join Redmayne Bentley
Talk to us now about opening a new account or transferring your account from another provider
0113 243 6941
Get in touch today
Contact your local office
Contact your local office to find out more
The value of your investments and the income from them may go down as well as up, and you could get back less than you invested.
Continuing our Personal Service: View our Latest COVID-19 Update: 17th May 2022
We use cookies on this site to improve your experience and help us provide you with a better website. An explanation of the cookies we use and their purpose can be found within our Cookie Policy. Your continued use of this site means you consent to the use of cookies.